When Bad Policy = Bad Business Models = Bad Public Health

Key takeaways

The pandemic highlighted deep-rooted flaws in the U.S. healthcare system, particularly at the intersection of business, policy, and public health.
Poor policies can lead to flawed business models, particularly in critical sectors like vaccines, antibiotics, and diagnostics.
Vaccine strategies require new business models that accommodate the unique nature of public health emergencies.
New antibiotic development faces profitability challenges due to limitations on use and reimbursement models that don't support innovation.
Diagnostics are undervalued in the healthcare system; better reimbursement policies could encourage investment and innovation.
Future pandemic preparedness must include robust policy frameworks that ensure public access to tests and treatments without financial barriers.
Regulation must adapt to rapidly evolving healthcare technologies to enable effective responses to public health crises.

Summary

The Intersection of Health Policy and Business

The discussion opens with the realization that the coronavirus pandemic has not only disrupted health systems but has also exposed significant systemic flaws. Healthcare is a unique sector where policy dictates business practices, and poor policy leads to inadequate business models. This relationship has vital implications for public health, as exemplified by historical failures in vaccine, antibiotic, and diagnostic markets.

The Vaccine Market Dilemma

The episode dives into the specifics of the vaccine market, highlighting how vaccines often turn into commodity products subject to low pricing. There is a difficulty in sustaining business models, especially when urgency fades post-crisis. Companies face pressures to produce vaccines quickly, and once the threat is neutralized, market demand evaporates, leaving businesses in a precarious position.

Antibiotic Market Challenges

Similar challenges exist in the antibiotic market, where the focus on preventing resistance complicates profitability. New antibiotics are often reserved for last-resort cases, limiting their use and creating unsustainable business models. The speakers emphasize the need for policy-driven incentives that would allow for a viable market for novel antibiotics.

Business Models in Diagnostics

Diagnostics have faced considerable challenges due to low reimbursement rates and being perceived as commodities. There is a disconnect between the value of diagnostics in preventive healthcare and the financial return for providers. The hosts discuss how clearer policies regarding testing and reimbursement could mitigate these issues.

Policy Responses to Future Pandemics

To prepare for future pandemics, the speakers suggest a combination of policy measures that guarantee testing access and provide reimbursement for relevant treatments. They advocate for a need to revise the structures that govern healthcare so that innovation can be fostered, especially in pandemic scenarios. A balance between regulation and the rapid adaptability of the healthcare market is essential for effective responses.

Regulatory Evolution and Market Innovation

The episode concludes with reflections on the need for regulatory frameworks to evolve alongside medical innovations. Outdated regulations may hinder the deployment of new technologies such as telehealth and remote diagnostics, underscoring the importance of continuously adapting policies to match evolving healthcare landscapes.

Show notes

with @JorgeCondeBio, @julesyoo, and @omnivorousread

In some ways, the coronavirus feels like it came out of nowhere—a kind of Black Swan event. But at the same time, it's been exposing a lot of the fundamental flaws in our healthcare system that now feel like a perfect storm coming together... and have hurt our ability to address the problem that we should really have seen coming.

In this episode, a16z General Partners Jorge Conde and Julie Yoo talk with Hanne Tidnam about some of those big forces and dynamics in the healthcare system, at the intersection of business, policy, and public health: how in healthcare like perhaps nowhere else, broken policy can lead to broken business models that, in the wrong circumstances, can then lead major failures in public health like the one we’re seeing today; where we’ve seen this before, in the markets of vaccines, antibiotics, and diagnostics; and what should be different next time, so that when a new pandemic hits we aren’t facing another perfect storm.

Stay Updated:

Find a16z on YouTube: YouTube

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Show on Spotify

Listen to the a16z Show on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.